P119 - Lowering Blood Glucose with Tetrahydrocannabivarin (THCV): What Does the Literature Say?

Rimonabant, which was submitted to the Food and Drug Administration for approval in 2005, significantly decreased body weight and A1C in randomized, controlled trials. However, its application was withdrawn because of significant psychiatric side effects, including depression and suicide ideation. THCV, in contrast, has not been shown to exhibit psychiatric side effects in studies similar to Rimonabant. This poster highlights the literature available regarding the potential to lower blood glucose with THCV, an inverse agonist/selective antagonist of Cannabinoid receptor 1 (CB1).